We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Definitive Tests for Irritable Bowel Syndrome Developed

By LabMedica International staff writers
Posted on 24 May 2015
In the clinical evaluation of chronic diarrhea, common differential diagnoses include diarrhea-predominant irritable bowel syndrome (D-IBS), inflammatory bowel disease (IBD) and celiac disease. More...


Although the anti-tissue transglutaminase antibody (anti-tTG) has proven to be an excellent biomarker for identifying celiac disease, D-IBS remains a diagnosis of exclusion since the clinical criteria for IBS, do not exclude IBD.

Scientists at Cedars-Sinai Medical Center (Los Angeles, CA, USA) and their collaborators recruited a total of 2,681 subjects. This included 2,375 D-IBS subjects, 43 healthy subjects, 121 celiac and 142 IBD subjects which included 73 with Crohn’s and 69 ulcerative colitis patients. IBS subjects were on average 3.9 years older than the non-IBS groups. There were no differences in sex distribution of IBS and non-IBS subjects; however, percentage of females was greater in the healthy controls, IBS and celiac groups as compared with the IBD group.

Plasma was collected from all subjects and tested by enzyme-linked immunosorbent assay for antibodies to cytolethal distending toxin B (CdtB) and vinculin. Tetramethylbenzidine (TMB) substrate solution was used for visualization and immediately read on a BioTek Synergy HT plate reader (Winooski, VT, USA). The optical densities (OD) were read for 90 minutes at 370 nm and used to compare levels of anti-CdtB or anti-vinculin. Raw OD values were used for the data analysis.

Using optical density levels, anti-CdtB antibody levels in D-IBS subjects were 2.53 ± 0.69 which were significantly higher than healthy subjects at 1.81 ± 0.73, Crohn’s disease at 1.72 ± 0.81, ulcerative colitis at 1.54 ±0.68 and celiac disease at 2.23±0.70. There were no differences in anti-CdtB levels between healthy subjects and IBD subjects; however, subjects with celiac disease had higher anti-CdtB levels than all other non-IBS groups. The tests are marketed under the name IBSchek and are produced by Commonwealth Laboratories Inc. (Salem, MA, USA).

Mark Pimentel, MD, who created the tests and is the senior author of the study, said, “Having an early diagnosis means patients can avoid years of invasive tests and visits to specialists that often leave them with more questions than answers. With these new blood tests, many patients will now be able to proceed right to therapy for their condition.” The study was published on May 13, 2015, in the journal Public Library of Science ONE.

Related Links:

Cedars-Sinai Medical Center 
BioTek 
Commonwealth Laboratories Inc.



New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Cell and Tissue Culture Plastics
Diamond® SureGro™ Cell and Tissue Culture Plastics
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.